Admit it -- you've probably at least considered buying Illumina stock since the company announced its acquisition of Solexa. Motley Fool has an article on Illumina's earnings with a quick analysis of the company's numbers and position in the competitive landscape. One interesting tidbit the story points out: "its bottom line was eroded by $8.7 million" thanks to the eagerness with which employees have been cashing in their stock options.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.